Company intelligence / Profile preview

Euprotec

Manchester, Greater Manchester, UKevotec.com ↗

Ownership: Private
Employees: ~19
Development stage: Preclinical

Overview

Prior to its acquisition by Evotec in May 2014, Euprotec was recognized as a world leader in infectious disease and respiratory biology CRO services. It provided comprehensive support for client drug discovery programs—including preclinical efficacy models, PKPD profiling, susceptibility testing, mechanism of action determination, and ADME/PK assays—enabling progression from early discovery through late-stage preclinical development.

Therapeutic areas: Infectious Diseases
Modalities: Small moleculeBiologic
Industry: Contract Research Organization

Beyond the preview

Go deeper on Euprotec.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Euprotec.

Explore the full profile